Search research articles
Contact Us
Filters
Showing results (11-20 of 332) with videos related to
Page
of 34
Sort By:
Current Alzheimer Research
|
April 4, 2014
A new regulatory road-map for Alzheimer's disease drug development
Robert E Becker, Nigel H Greig
Science Translational Medicine
|
December 15, 2010
Lost in translation: neuropsychiatric drug development
Robert E Becker, Nigel H Greig
Current Pharmaceutical Design
|
April 12, 2016
Editorial: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part B)
Mohammad A Kamal, Nigel H Greig
Journal of Alzheimer'S Disease : JAD
|
March 1, 2019
Can We Prevent Dementia and Not Prevent Neurons from Dying?
Robert E Becker, Nigel H Greig
Current Alzheimer Research
|
March 26, 2014
Advances in understanding Alzheimer's disease, and the contributions of current Alzheimer research: ten years on and beyond
Nigel H Greig, Debomoy K Lahiri
Trends in Neurosciences
|
February 24, 2019
Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis
Stephen D Skolnick, Nigel H Greig
Future Medicinal Chemistry
|
March 27, 2019
Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide
William A Banks, Nigel H Greig
Current Drug Targets
|
July 24, 2004
A new Alzheimer's disease interventive strategy: GLP-1
Tracy Ann Perry, Nigel H Greig
Current Pharmaceutical Design
|
September 23, 2016
Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part C))
Mohammad A Kamal, Nigel H Greig
Journal of Clinical Psychopharmacology
|
January 15, 2009
Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?
Robert E Becker, Nigel H Greig
Page
of 34
Search research articles
Search
Showing results (11-20 of 332) with videos related to
Sort By:
Page
of 34
Current Alzheimer Research
|
April 4, 2014
A new regulatory road-map for Alzheimer's disease drug development
Robert E Becker, Nigel H Greig
Science Translational Medicine
|
December 15, 2010
Lost in translation: neuropsychiatric drug development
Robert E Becker, Nigel H Greig
Current Pharmaceutical Design
|
April 12, 2016
Editorial: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part B)
Mohammad A Kamal, Nigel H Greig
Journal of Alzheimer'S Disease : JAD
|
March 1, 2019
Can We Prevent Dementia and Not Prevent Neurons from Dying?
Robert E Becker, Nigel H Greig
Current Alzheimer Research
|
March 26, 2014
Advances in understanding Alzheimer's disease, and the contributions of current Alzheimer research: ten years on and beyond
Nigel H Greig, Debomoy K Lahiri
Trends in Neurosciences
|
February 24, 2019
Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis
Stephen D Skolnick, Nigel H Greig
Future Medicinal Chemistry
|
March 27, 2019
Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide
William A Banks, Nigel H Greig
Current Drug Targets
|
July 24, 2004
A new Alzheimer's disease interventive strategy: GLP-1
Tracy Ann Perry, Nigel H Greig
Current Pharmaceutical Design
|
September 23, 2016
Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part C))
Mohammad A Kamal, Nigel H Greig
Journal of Clinical Psychopharmacology
|
January 15, 2009
Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?
Robert E Becker, Nigel H Greig
Page
of 34